It's less of an approval hedge and more of a lock on all best-in-class third agent combinations
Partnering with Tibotec also conveys the appearance that the HIV space remains somewhat competitive when in fact it's just GILD competing against itself. It's in GILD's best interest to favor marketing the higher margin in-house combos over partnered combos if both drugs are eventually approved.
After Truvada goes generic competitors will still need a boosting agent like GILD's cobicstat to compete directly with the Quad (if approved). This provides another barrier to competition.
Market Data 
Markets 
AI
